BioMarin Pharmaceutical | BMRN - Interest Expense On Debt

Stock Price
57.60
Daily Change
-0.36 -0.61%
Monthly
-2.17%
Yearly
-8.39%
Q1 Forecast
54.80

BioMarin Pharmaceutical reported $2.58M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 44.4M 4.15M Sep/2025
Amgen USD 685M 9M Sep/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Gilead Sciences USD 254M 6M Jun/2025
Incyte USD 592K 2K Sep/2025
Insmed USD 20.38M 863K Sep/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
PTC Therapeutics USD 2.64B 2.61B Sep/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 99.78M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Ultragenyx Pharmaceutical USD 14.15M 108K Sep/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 400K Sep/2025